Entera Bio Ltd. — Form SCHEDULE 13D
Filed August 4, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D
— Neutral
significance 48/100
What the filing says
Multiple BVF funds and related entities (Biotechnology Value Fund I LP, BVF II LP, Biotechnology Value Trading Fund OS LP, BVF Partners OS Ltd., and others), along with Mark N. Lampert, filed a joint Schedule 13D on August 4, 2026 regarding Entera Bio ordinary shares. The filing establishes coordinated ownership disclosure but does not specify the number of shares held, percentage stake, or acquisition date in this joint filing agreement excerpt.
Why this rating
Schedule 13D signals 5%+ stake by BVF entities in $84.6M company—material ownership threshold. Specifics (share count, %) absent here; cannot assess magnitude relative to company size without them.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.